An Internet-based survey of anaphylactic reactions to foods.
BACKGROUND
A favorable outcome of anaphylaxis depends on the rapidity of adequate initial management and epinephrine injection. However, few data on the management of anaphylactic reactions are available. The aim of this study was to investigate the management and awareness of anaphylaxis to foods by mean of an Internet-based survey.


METHODS
Visitors to a website with information on food allergy were invited to join the survey. Items in the survey included the management of anaphylactic reactions, investigations done by the diagnosing physician, and information given to the responder in anticipation of a new anaphylactic reaction.


RESULTS
Almost all of the 264 responders were from North America, Europe, Australia, or New Zealand (263/264). The most recent reaction was treated by epinephrine injection in 68.7% (180/262) of cases, or by antihistamines in 14.1% (37/262). Epinephrine was the first treatment for the most severe reaction in only 43.9% (101/230), while antihistamines were given first in 43.5% (100/230). One-third (62/210 = 29.5%) of the responders diagnosed by a physician received neither a diagnostic blood test nor a skin test. Responders diagnosed by an allergist were more often investigated (91/105 = 86.7%) than those diagnosed by a pediatrician or an internist (29/44 = 65.9%), a general practitioner (22/45 = 48.9%), or another physician (6/16 = 37.5%) (P < 0.001). Most responders had received instructions on how to deal with a new episode of anaphylaxis (244/263 = 92.8%). Responders instructed by an allergist were most frequently satisfied with the instructions (115/131 = 87.8%).


CONCLUSIONS
A large number of responders did not receive epinephrine for treatment of their most severe, or most recent anaphylactic reaction, and did not undergo allergy tests. The conventional management of anaphylaxis might still be improved.
Eigenmann
P A
PA
Department of Pediatrics, Division of Immunology and Allergy, Geneva, Switzerland.
Pastore
F D
FD
Zamora
S A
SA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology*; D001315:Australia / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D004837:Epinephrine / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D005260:Female; D005502:Food / Q000009:adverse effects*; D006306:Health Surveys; D006403:Hematologic Tests / Q000379:methods; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D020407:Internet; D008297:Male; D008875:Middle Aged; D009520:New Zealand / Q000453:epidemiology; D009656:North America / Q000453:epidemiology; D012882:Skin Tests / Q000379:methods
D004837:Epinephrine